# A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis

> **NCT07351968** · PHASE1 · RECRUITING · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Moderate Pain in Knee Osteoarthritis
- Severe Pain in Knee Osteoarthritis

## Interventions

- **DRUG:** HRS-2129 Tablet
- **DRUG:** Celecoxib capsule
- **DRUG:** Celecoxib Capsule Placebo
- **DRUG:** HRS-2129 Tablet Placebo

## Key facts

- **NCT ID:** NCT07351968
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07351968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07351968, "A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07351968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*